(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are TOP Ships, Vascular Biogenics Ltd., and Okta.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | TOP Ships (TOPS) | 0.96 | 25.49% | 2023-03-01 21:10:08 |
| 2 | Vascular Biogenics Ltd. (VBLT) | 0.19 | 18.74% | 2023-03-02 03:48:16 |
| 3 | Okta (OKTA) | 80.40 | 12.54% | 2023-03-02 15:49:00 |
| 4 | TOR Minerals International (TORM) | 2.75 | 12.24% | 2023-03-01 21:11:09 |
| 5 | Salesforce (CRM) | 186.25 | 11.29% | 2023-03-02 15:57:32 |
| 6 | ImmunoGen (IMGN) | 4.46 | 10.95% | 2023-03-02 15:58:08 |
| 7 | Bilibili (BILI) | 21.64 | 9.99% | 2023-03-02 15:52:59 |
| 8 | DexCom (DXCM) | 121.30 | 9.52% | 2023-03-02 15:56:01 |
| 9 | CRH PLC (CRH) | 51.85 | 9.26% | 2023-03-02 15:57:29 |
| 10 | Village Bank and Trust Financial Corp. (VBFC) | 58.98 | 9.22% | 2023-03-02 03:46:17 |
The three biggest losers today are Adial Pharmaceuticals, Box, and Zai Lab.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Adial Pharmaceuticals (ADILW) | 0.06 | -20.73% | 2023-03-02 15:07:09 |
| 2 | Box (BOX) | 29.17 | -13.12% | 2023-03-02 15:53:56 |
| 3 | Zai Lab (ZLAB) | 37.03 | -8.3% | 2023-03-02 15:54:09 |
| 4 | Addex Therapeutics Ltd (ADXN) | 2.02 | -7.76% | 2023-03-02 15:11:13 |
| 5 | AMC (AMC) | 6.11 | -7.08% | 2023-03-02 15:51:18 |
| 6 | Theravance Biopharma (TBPH) | 10.04 | -7.04% | 2023-03-01 19:08:10 |
| 7 | United-Guardian (UG) | 10.63 | -6.92% | 2023-03-02 01:14:08 |
| 8 | argenx SE (ARGX) | 344.20 | -6.71% | 2023-03-02 15:52:56 |
| 9 | Tucows (TCX) | 21.66 | -6.31% | 2023-03-01 19:14:09 |
| 10 | Plug Power (PLUG) | 13.32 | -6.26% | 2023-03-02 15:59:57 |
Winners today
1. TOP Ships (TOPS) – 25.49%
Top Ships Inc. owns and operates tanker vessels worldwide. The company's medium range tanker vessels transport crude oil, petroleum products, and bulk liquid chemicals. As of December 31, 2020, it had a fleet with a total capacity of 672,396 deadweight tonnes (dwt) consisting of four 50,000 dwt product/chemical tankers and three 157,000 dwt tankers. The company was formerly known as Top Tankers Inc. and changed its name to Top Ships Inc. in December 2007. Top Ships Inc. was founded in 2000 and is based in Maroussi, Greece.
NASDAQ ended the session with TOP Ships jumping 25.49% to $0.96 on Thursday, following the last session’s upward trend. NASDAQ rose 0.73% to $11,462.98, after four sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, TOP Ships has a trailing twelve months EPS of $-4.46.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.83%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 53.5%, now sitting on 69.9M for the twelve trailing months.
More news about TOP Ships.
2. Vascular Biogenics Ltd. (VBLT) – 18.74%
Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company's program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.
NASDAQ ended the session with Vascular Biogenics Ltd. jumping 18.74% to $0.19 on Thursday, after three consecutive sessions in a row of gains. NASDAQ rose 0.73% to $11,462.98, after four sequential sessions in a row of losses, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Vascular Biogenics Ltd. has a trailing twelve months EPS of $-0.555.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -102.32%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 141.7%, now sitting on 854k for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 16.7% and a negative 15.4%, respectively.
More news about Vascular Biogenics Ltd..
3. Okta (OKTA) – 12.54%
Okta, Inc. provides identity solutions for enterprises, small and medium-sized businesses, universities, non-profits, and government agencies in the United States and internationally. The company offers Okta Identity Cloud, a platform that offers a suite of products and services, such as Universal Directory, a cloud-based system of record to store and secure user, application, and device profiles for an organization; Single Sign-On that enables users to access applications in the cloud or on-premise from various devices; Adaptive Multi-Factor Authentication provides a layer of security for cloud, mobile, Web applications, and data; Lifecycle Management that enables IT organizations or developers to manage a user's identity throughout its lifecycle; API Access Management that enables organizations to secure APIs; Access Gateway that enables organizations to extend the Okta Identity Cloud from the cloud to their existing on-premise applications; and Advanced Server Access to secure cloud infrastructure. It also provides Auth0 products, including Universal Login that allows customers to provide login experience across different applications and devices; Attack Protection, a suite of security capabilities that protect from malicious traffics; Adaptive Multi-Factor Authentication that minimizes friction to end users; Passwordless authentication enables users to login without a password and supports in various login methods; Machine to Machine provides standards-based authentication and authorization; private Cloud that allows customers to run a dedicated cloud instance of Auth0; and Organizations that enables customers to independent configurations, login experiences, and security options. It offers customer support, training, and professional services. It sells its products directly to customers through sales force and channel partners. The company was formerly known as Saasure, Inc. Okta, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
NASDAQ ended the session with Okta rising 12.54% to $80.40 on Thursday, following the last session’s upward trend. NASDAQ rose 0.73% to $11,462.98, after four consecutive sessions in a row of losses, on what was a somewhat up trend exchanging session today.
For first-quarter fiscal 2024, Okta expects revenues of $509-$511 million, which indicates year-over-year growth of 23%.
Earnings Per Share
As for profitability, Okta has a trailing twelve months EPS of $-2.09.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.86%.
Previous days news about Okta
- Okta (okta) surpasses Q4 earnings and revenue estimates. According to Zacks on Wednesday, 1 March, "While Okta has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about Okta.
4. TOR Minerals International (TORM) – 12.24%
TOR Minerals International, Inc. produces and sells specialty mineral products in the United States, Europe, and Asia. The company offers alumina trihydrate and boehmite halogen-free flame retardant and smoke suppressant fillers for plastics, rubber, and specialty applications; and beige and gray colored titanium dioxide (TiO2) pigments for use in paints, coatings, plastics, paper, and various other products. It also provides white TiO2, a pigment to add whiteness and opacity to paints and coatings, plastics, and other materials; and engineered fillers for use in plastics, paints, coatings, catalysts, and industrial products. The company was founded in 1973 and is headquartered in Corpus Christi, Texas.
NASDAQ ended the session with TOR Minerals International rising 12.24% to $2.75 on Thursday while NASDAQ jumped 0.73% to $11,462.98.
Earnings Per Share
As for profitability, TOR Minerals International has a trailing twelve months EPS of $-0.52.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3%.
Moving Average
TOR Minerals International’s value is way above its 50-day moving average of $2.49 and above its 200-day moving average of $2.50.
Revenue Growth
Year-on-year quarterly revenue growth declined by 10.5%, now sitting on 39.43M for the twelve trailing months.
Volume
Today’s last reported volume for TOR Minerals International is 2510 which is 294.03% above its average volume of 637.
Yearly Top and Bottom Value
TOR Minerals International’s stock is valued at $2.75 at 16:32 EST, way below its 52-week high of $3.10 and way higher than its 52-week low of $2.01.
More news about TOR Minerals International.
5. Salesforce (CRM) – 11.29%
Salesforce, Inc. provides customer relationship management technology that brings companies and customers together worldwide. Its Customer 360 platform empowers its customers to work together to deliver connected experiences for their customers. The company's service offerings include Sales to store data, monitor leads and progress, forecast opportunities, gain insights through analytics and relationship intelligence, and deliver quotes, contracts, and invoices; and Service that enables companies to deliver trusted and highly personalized customer service and support at scale. Its service offerings also comprise flexible platform that enables companies of various sizes, locations, and industries to build business apps to bring them closer to their customers with drag-and-drop tools; online learning platform that allows anyone to learn in-demand Salesforce skills; and Slack, a system of engagement. In addition, the company's service offerings include Marketing offering that enables companies to plan, personalize, and optimize one-to-one customer marketing journeys; and Commerce offering, which empowers brands to unify the customer experience across mobile, web, social, and store commerce points. Further, its service offerings comprise Tableau, an end-to-end analytics solution serving various enterprise use cases; and MuleSoft, an integration offering that allows its customers to unlock data across their enterprise. The company provides its service offering for customers in financial services, healthcare and life sciences, manufacturing, and other industries. It also offers professional services; and in-person and online courses to certify its customers and partners on architecting, administering, deploying, and developing its service offerings. The company provides its services through direct sales; and consulting firms, systems integrators, and other partners. Salesforce, Inc. was incorporated in 1999 and is headquartered in San Francisco, California.
NYSE ended the session with Salesforce jumping 11.29% to $186.25 on Thursday while NYSE rose 0.49% to $15,512.36.
Salesforce stock price: CRM jumps to highest level in 11 monthsFor the fourth quarter, Salesforce produced $1.68 in adjusted earnings per share (EPS) on revenue of $8.38 billion. , In addition, Salesforce said it would earn $1.60 per share at the bottom end of the range, while analysts had projected $1.32 per share.
Earnings Per Share
As for profitability, Salesforce has a trailing twelve months EPS of $4.38.
PE Ratio
Salesforce has a trailing twelve months price to earnings ratio of 42.52. Meaning, the purchaser of the share is investing $42.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.48%.
Sales Growth
Salesforce’s sales growth is 9.2% for the current quarter and 9% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.2%, now sitting on 30.29B for the twelve trailing months.
Previous days news about Salesforce
- Salesforce inc. (crm stock) could rise towards the 178 level. According to FXStreet on Wednesday, 1 March, "Today’s instrument is the Salesforce Inc. stock traded in NYSE exchange under the ticker CRM."
More news about Salesforce.
6. ImmunoGen (IMGN) – 10.95%
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
NASDAQ ended the session with ImmunoGen rising 10.95% to $4.46 on Thursday, after two sequential sessions in a row of gains. NASDAQ rose 0.73% to $11,462.98, after four successive sessions in a row of losses, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.252.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -157.66%.
Volatility
ImmunoGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.29%, a negative 1.61%, and a positive 2.91%.
ImmunoGen’s highest amplitude of average volatility was 3.35% (last week), 3.23% (last month), and 2.91% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is a negative 76.5% and a negative 180%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 66.9%, now sitting on 95.61M for the twelve trailing months.
More news about ImmunoGen.
7. Bilibili (BILI) – 9.99%
Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, and live broadcasting. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
NASDAQ ended the session with Bilibili jumping 9.99% to $21.64 on Thursday, following the last session’s upward trend. NASDAQ rose 0.73% to $11,462.98, after four successive sessions in a row of losses, on what was a somewhat up trend trading session today.
Bilibili (bili) reports Q4 loss, tops revenue estimatesWhile Bilibili has underperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?
Earnings Per Share
As for profitability, Bilibili has a trailing twelve months EPS of $-1.35.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.57%.
Sales Growth
Bilibili’s sales growth is 11% for the present quarter and 17.8% for the next.
Volume
Today’s last reported volume for Bilibili is 15189200 which is 53.05% above its average volume of 9924040.
More news about Bilibili.
8. DexCom (DXCM) – 9.52%
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
NASDAQ ended the session with DexCom jumping 9.52% to $121.30 on Thursday, following the last session’s downward trend. NASDAQ jumped 0.73% to $11,462.98, after four sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $5.2.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 23.3. Meaning, the purchaser of the share is investing $23.3 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.19%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 112.5% and 35.3%, respectively.
Yearly Top and Bottom Value
DexCom’s stock is valued at $121.30 at 16:32 EST, under its 52-week high of $134.76 and way above its 52-week low of $66.89.
More news about DexCom.
9. CRH PLC (CRH) – 9.26%
CRH plc, through its subsidiaries, manufactures and distributes building materials. It operates in three segments: Americas Materials, Europe Materials, and Building Products. The company manufactures and supplies cement, lime, aggregates, precast, ready mixed concrete, and asphalt products; concrete masonry and hardscape products comprising pavers, blocks and kerbs, retaining walls, and related patio products; and glass and glazing products, including architectural glass, custom-engineered curtain and window walls, architectural windows, storefront systems, doors, skylights, and architectural hardware. It also offers precast concrete and polymer-based products, such as underground vaults, drainage pipes and structures, utility enclosures, and modular precast structures to the water, energy, communication, transportation, and building structures markets; and construction accessories, such as anchoring, fixing, and connection solutions, as well as lifting systems, formwork accessories, and other accessories used in construction applications. In addition, the company offers network access products, which include composite access chambers, covers, passive safety systems, retention sockets, sealants, and meter boxes; and paving and construction services. Further, it provides building and civil engineering contracting, contract surfacing, operates logistics and owned railway infrastructure; sells and distributes cement; and supplies access chambers and ducting products. It serves governments, contractors, homebuilders, homeowners, and sub-contractors. The company operates primarily in the Republic of Ireland, the United Kingdom, the rest of Europe, the United States, and internationally. CRH plc was founded in 1936 and is headquartered in Dublin, Ireland.
NYSE ended the session with CRH PLC jumping 9.26% to $51.85 on Thursday while NYSE jumped 0.49% to $15,512.36.
Earnings Per Share
As for profitability, CRH PLC has a trailing twelve months EPS of $1.42.
PE Ratio
CRH PLC has a trailing twelve months price to earnings ratio of 36.57. Meaning, the purchaser of the share is investing $36.57 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.64%.
More news about CRH PLC.
10. Village Bank and Trust Financial Corp. (VBFC) – 9.22%
Village Bank and Trust Financial Corp. primarily operates as the bank holding company for Village Bank that provides banking and related financial products and services to small and medium sized businesses, professionals, and individuals. It operates in two segments, Traditional Commercial Banking and Mortgage Banking. The company accepts checking, savings, money market, and individual retirement accounts, as well as certificates of deposit and other depository services. It also provides secured and unsecured commercial business loans for various purposes, such as funding working capital needs, business expansion, and purchase of equipment and machinery; loans for acquiring, developing, constructing, and owning commercial real estate properties; and secured and unsecured consumer loans for financing automobiles, home improvements, education, and personal investments, as well as originates mortgage loans, real estate construction loans, and acquisition loans for sale in the secondary market. In addition, the company offers online banking, mobile banking, and remote deposit capture services for business clients. It provides its products and services through nine full-service branch banking offices and a mortgage loan production office in Central Virginia in the counties of Chesterfield, Hanover, Henrico, Powhatan, and James City. Village Bank and Trust Financial Corp. was founded in 1999 and is headquartered in Midlothian, Virginia.
NASDAQ ended the session with Village Bank and Trust Financial Corp. jumping 9.22% to $58.98 on Thursday while NASDAQ rose 0.73% to $11,462.98.
Earnings Per Share
As for profitability, Village Bank and Trust Financial Corp. has a trailing twelve months EPS of $7.89.
PE Ratio
Village Bank and Trust Financial Corp. has a trailing twelve months price to earnings ratio of 7.47. Meaning, the purchaser of the share is investing $7.47 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.34%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.5%, now sitting on 32.61M for the twelve trailing months.
Moving Average
Village Bank and Trust Financial Corp.’s value is above its 50-day moving average of $54.93 and way above its 200-day moving average of $51.12.
Yearly Top and Bottom Value
Village Bank and Trust Financial Corp.’s stock is valued at $58.98 at 16:32 EST, under its 52-week high of $64.17 and way higher than its 52-week low of $43.97.
More news about Village Bank and Trust Financial Corp..
Losers Today
1. Adial Pharmaceuticals (ADILW) – -20.73%
NASDAQ ended the session with Adial Pharmaceuticals falling 20.73% to $0.06 on Thursday while NASDAQ rose 0.73% to $11,462.98.
Yearly Top and Bottom Value
Adial Pharmaceuticals’s stock is valued at $0.06 at 16:32 EST, under its 52-week high of $0.06 and way above its 52-week low of $0.04.
More news about Adial Pharmaceuticals.
2. Box (BOX) – -13.12%
Box, Inc. provides a cloud content management platform that enables organizations of various sizes to manage and share their content from anywhere on any device. The company's Software-as-a-Service platform enables users to collaborate on content internally and with external parties, automate content-driven business processes, develop custom applications, and implement data protection, security, and compliance features to comply with legal and regulatory requirements, internal policies, and industry standards and regulations. It offers web, mobile, and desktop applications for cloud content management on a platform for developing custom applications, as well as industry-specific capabilities. As of January 31, 2022, the company had approximately 100,000 paying organizations, and its solution was offered in 25 languages. It serves financial services, health care, government, and legal services industries in the United States and internationally. The company was formerly known as Box.net, Inc. and changed its name to Box, Inc. in November 2011. Box, Inc. was incorporated in 2005 and is headquartered in San Francisco Bay Area, California.
NYSE ended the session with Box falling 13.12% to $29.17 on Thursday, after two consecutive sessions in a row of gains. NYSE jumped 0.49% to $15,512.36, following the last session’s upward trend on what was a somewhat positive trend trading session today.
Jack in the box (jack) Q1 earnings: taking a look at key metrics versus estimatesHere is how Jack In The Box performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:, View all Key Company Metrics for Jack In The Box here>>>Shares of Jack In The Box have returned +3.2% over the past month versus the Zacks S&P 500 composite’s -2.5% change.
Earnings Per Share
As for profitability, Box has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34%.
Previous days news about Box
- According to Zacks on Tuesday, 28 February, "Moreover, improved capabilities in Box Sign are likely to have continued helping customers to move their signature transactions to the cloud.", "The company announced the general availability of an enhanced Box app for Zoom that enables customers to automatically save select Zoom recordings directly to Box."
- What's in store for jack in the box (jack) in Q1 earnings?. According to Zacks on Tuesday, 28 February, "Jack in the Box Inc. (JACK Quick QuoteJACK – Free Report) is scheduled to report first-quarter fiscal 2023 results on Mar 1. ", "Our proven model predicts an earnings beat for Jack in the Box this time around. "
- Jack in the box (jack) surpasses Q1 earnings and revenue estimates. According to Zacks on Wednesday, 1 March, "While Jack In The Box has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?", "Jack In The Box (JACK Quick QuoteJACK – Free Report) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.76 per share. "
More news about Box.
3. Zai Lab (ZLAB) – -8.3%
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, the company develops CLN-081 for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab that inhibits interactions between PD-1 and its ligands; ZL-2309, an orally active, selective, and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; KarXT for the treatment of psychiatric and neurological conditions; ZL-2313, an investigational inhibitor of triple-mutant EGFR harboring; ZL-2314, an investigational inhibitor of double-mutant EGFR harboring; and Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China.
NASDAQ ended the session with Zai Lab falling 8.3% to $37.03 on Thursday, after two sequential sessions in a row of gains. NASDAQ jumped 0.73% to $11,462.98, after four sequential sessions in a row of losses, on what was a somewhat positive trend exchanging session today.
Earnings Per Share
As for profitability, Zai Lab has a trailing twelve months EPS of $-3.46.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.05%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.5%, now sitting on 196.61M for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 22.8% and positive 48.8% for the next.
More news about Zai Lab.
4. Addex Therapeutics Ltd (ADXN) – -7.76%
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health; and research collaboration agreement with Indivior PLC. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
NASDAQ ended the session with Addex Therapeutics Ltd dropping 7.76% to $2.02 on Thursday, following the last session’s upward trend. NASDAQ rose 0.73% to $11,462.98, after four consecutive sessions in a row of losses, on what was a somewhat bullish trend trading session today.
Earnings Per Share
As for profitability, Addex Therapeutics Ltd has a trailing twelve months EPS of $-3.77.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -202.67%.
Yearly Top and Bottom Value
Addex Therapeutics Ltd’s stock is valued at $2.02 at 16:32 EST, way under its 52-week high of $5.45 and way higher than its 52-week low of $0.55.
Revenue Growth
Year-on-year quarterly revenue growth declined by 45.1%, now sitting on 1.25M for the twelve trailing months.
Volume
Today’s last reported volume for Addex Therapeutics Ltd is 177032 which is 41.56% below its average volume of 302971.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Addex Therapeutics Ltd’s EBITDA is 0.2.
More news about Addex Therapeutics Ltd.
5. AMC (AMC) – -7.08%
AMC Entertainment Holdings, Inc., through its subsidiaries, engages in the theatrical exhibition business. The company owns, operates, or has interests in theatres in the United States and Europe. As of March 1, 2022, it operated approximately 950 theatres and 10,600 screens. The company was founded in 1920 and is headquartered in Leawood, Kansas.
NYSE ended the session with AMC falling 7.08% to $6.11 on Thursday while NYSE rose 0.49% to $15,512.36.
Earnings Per Share
As for profitability, AMC has a trailing twelve months EPS of $-39.15.
Sales Growth
AMC’s sales growth is negative 13.6% for the present quarter and 23.6% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 30.8% and 75.4%, respectively.
Previous days news about AMC
- : AMC stock keeps rallying after popcorn collaboration with Walmart announced ahead of earnings. According to MarketWatch on Tuesday, 28 February, "Shares of AMC Entertainment Holdings Inc. rallied 2.8% in morning trading Tuesday, AMC said all of its new lines of "AMC Perfectly Popcorn" ready-to-eat and microwave popcorn will be sold exclusively at discount retail giant Walmart’s stores March 11, "just in time for the Academy Awards, which airs on March 12." The stock’s rally comes just before AMC reveals its fourth-quarter results, which are expected after the closing bell. ", "On March 11, which is Oscars weekend, we will enter the multi-billion-dollar retail popcorn industry with at-home popcorn that features the authentic taste of real movie theatre popcorn," said AMC Chief Executive Adam Aron. "
- AMC entertainment earnings: AMC stock craters as bulls take profits following consensus beat. According to FXStreet on Wednesday, 1 March, "The most positive sign from the earnings call came when Adam Aron said AMC saw a 44% YoY rise in box office attendance at the start of the present quarter - Q1.", "Besides AMC stock had already rallied 69% over the previous two weeks, so it is unsurprising that bullsdecided to cash in their receipts."
More news about AMC.
6. Theravance Biopharma (TBPH) – -7.04%
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands.
NASDAQ ended the session with Theravance Biopharma dropping 7.04% to $10.04 on Thursday, following the last session’s downward trend. NASDAQ rose 0.73% to $11,462.98, after four consecutive sessions in a row of losses, on what was a somewhat up trend trading session today.
Earnings Per Share
As for profitability, Theravance Biopharma has a trailing twelve months EPS of $-0.91.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -179.84%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 2%, now sitting on 51.35M for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Theravance Biopharma’s EBITDA is 8.78.
Moving Average
Theravance Biopharma’s value is below its 50-day moving average of $10.76 and higher than its 200-day moving average of $9.90.
More news about Theravance Biopharma.
7. United-Guardian (UG) – -6.92%
United-Guardian, Inc. manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products in the United States and internationally. It offers cosmetic ingredients, including LUBRAJEL line of water-based moisturizing and lubricating gel formulations; LUBRAJEL NATURAL consisting of natural ingredients for cosmetic use; LUBRAJEL MARINE; LUBRASIL II SB, a special formulation of LUBRAJEL in which silicone oil is incorporated into a LUBRAJEL base; LUBRAJEL II XD; B-122, a powdered lubricant that is used in the manufacture of pressed powders, eyeliners, rouges, and industrial products; KLENSOFT, a surfactant, which is used in shampoos, shower gels, makeup removers, and other cosmetic formulations; and ORCHID COMPLEX, an oil-soluble base for skin creams, lotions, cleansers, and other cosmetics. The company's medical lubricants comprise LUBRAJEL RR and RC, which are water-based lubricant gels for urinary catheters; LUBRAJEL MG to lubricate urinary catheters, pre-lubricated enema tips, and other medical devices; LUBRAJEL LC and LUBRAJEL FA that are LUBRAJEL formulations for oral care; and LUBRAJEL FLUID to lubricate water-soluble products. Its pharmaceutical products consist of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial product to treat infections in the urinary bladder, and localized infections in the peritoneum, as well as eye, ear, nose and throat, and sinuses. The company's industrial products include DESELEX, a sequestering and chelating agent used for manufacturing detergents; and THOROCLENS, a chlorine-based industrial cleanser. It also conducts research and development primarily related to the development of cosmetic ingredients. The company markets its products through marketing partners, distributors, and wholesalers. United-Guardian, Inc. was founded in 1942 and is based in Hauppauge, New York.
NASDAQ ended the session with United-Guardian falling 6.92% to $10.63 on Thursday while NASDAQ rose 0.73% to $11,462.98.
Earnings Per Share
As for profitability, United-Guardian has a trailing twelve months EPS of $0.65.
PE Ratio
United-Guardian has a trailing twelve months price to earnings ratio of 16.35. Meaning, the purchaser of the share is investing $16.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.71%.
Moving Average
United-Guardian’s worth is under its 50-day moving average of $11.22 and way below its 200-day moving average of $13.70.
Earnings Before Interest, Taxes, Depreciation, and Amortization
United-Guardian’s EBITDA is 62.91.
Revenue Growth
Year-on-year quarterly revenue growth declined by 24%, now sitting on 13.6M for the twelve trailing months.
Yearly Top and Bottom Value
United-Guardian’s stock is valued at $10.63 at 16:32 EST, way below its 52-week high of $26.09 and higher than its 52-week low of $10.12.
More news about United-Guardian.
8. argenx SE (ARGX) – -6.71%
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
NASDAQ ended the session with argenx SE falling 6.71% to $344.20 on Thursday, following the last session’s upward trend. NASDAQ jumped 0.73% to $11,462.98, after four successive sessions in a row of losses, on what was a somewhat positive trend trading session today.
Earnings Per Share
As for profitability, argenx SE has a trailing twelve months EPS of $-14.04.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 40.1% and 34.6%, respectively.
Sales Growth
argenx SE’s sales growth is 293.2% for the ongoing quarter and 494.6% for the next.
More news about argenx SE.
9. Tucows (TCX) – -6.31%
Tucows Inc. provides network access, domain name registration, email, mobile telephony, and other Internet services in Canada, the United States, and Europe. It operates through two segments, Network Access Services and Domain Services. The Network Access Services segment offers mobile phones and retail telephony services; fixed high-speed Internet access services; and professional services, including implementation, training, consulting, and software development and modification services, as well as operates Mobile Services Enabler platform that provides network access, provisioning, and billing services; The Domain Services segment offers wholesale and retail domain name registration services; portfolio services; and value-added services, such as hosted email, Internet security services, Internet hosting, WHOIS privacy, publishing tools, and other value-added services for end-users under the OpenSRS, eNom, Ascio, and Hover brands. The company was formerly known as Infonautics, Inc. and changed its name to Tucows Inc. in August 2001. Tucows Inc. was incorporated in 1992 and is headquartered in Toronto, Canada.
NASDAQ ended the session with Tucows sliding 6.31% to $21.66 on Thursday while NASDAQ rose 0.73% to $11,462.98.
Earnings Per Share
As for profitability, Tucows has a trailing twelve months EPS of $-1.44.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.04%.
Yearly Top and Bottom Value
Tucows’s stock is valued at $21.66 at 16:32 EST, way below its 52-week high of $72.98 and higher than its 52-week low of $21.58.
More news about Tucows.
10. Plug Power (PLUG) – -6.26%
Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including green hydrogen production, storage and delivery, and energy generation through mobile or stationary applications. The company provides proton exchange membrane (PEM), fuel cell and fuel processing technologies, and fuel cell/battery hybrid technologies, as well as related hydrogen and green hydrogen generation, storage, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled PEM fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; and GenFuel Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. It has strategic agreements with Airbus; Lhyfe; Edison Motors; Phillips 66; Apex Clean Energy; BAE Systems; and Universal Hydrogen Co. The company was founded in 1997 and is headquartered in Latham, New York.
NASDAQ ended the session with Plug Power falling 6.26% to $13.32 on Thursday while NASDAQ rose 0.73% to $11,462.98.
Plug Power (plug) reports Q4 earnings: what key metrics have to sayView all Key Company Metrics for Plug Power here>>>Shares of Plug Power have returned -12.6% over the past month versus the Zacks S&P 500 composite’s -2.5% change. , Here is how Plug Power performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Earnings Per Share
As for profitability, Plug Power has a trailing twelve months EPS of $-1.58.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -15.53%.
Yearly Top and Bottom Value
Plug Power’s stock is valued at $13.32 at 16:32 EST, way below its 52-week high of $32.05 and way above its 52-week low of $11.49.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 24.2% and 22.2%, respectively.
Sales Growth
Plug Power’s sales growth is 74.7% for the present quarter and 69.3% for the next.
Moving Average
Plug Power’s worth is way below its 50-day moving average of $14.96 and way under its 200-day moving average of $18.51.
Previous days news about Plug Power
- Plug Power (plug) reports Q4 loss, lags revenue estimates. According to Zacks on Wednesday, 1 March, "While Plug Power has outperformed the market so far this year, the question that comes to investors’ minds is: what’s next for the stock?"
More news about Plug Power.
Stay up to date with our winners and losers daily report
